• INCLUSION CRITERIA:

To be eligible for study participation, a volunteer must satisfy all of the following inclusion criteria:

1. Age greater than or equal to 18 years.
2. Documentation of HIV-1 infection by any licensed ELISA test and confirmed by a Western Blot.
3. Receiving a DHHS-approved ARV regimen, without evidence of previous virologic failure (confirmed HIV-RNA greater than or equal to 1000 copies/mL after achieving HIV-RNA < 50 copies/mL or HIV-RNA drop < 2 Log copies/mL at Week 24 after treatment initiation). Modifications in ARVs for toxicity or tolerability reasons are permitted.
4. HIV-1 RNA levels less than detectable by current commercial means (e.g., Roche Amplicor, b-DNA test) for a minimum of 12 months prior to screening at all time points, and with at least 2 measurements in this 12 month window.
5. HIV-1 RNA levels greater than or equal to 0.6 copies/mL by SCA at screening visit.
6. CD4 greater than or equal to 300 cells/mm(3) at pre-entry visit within 14 days prior to enrollment.
7. Ability to sign informed consent and willingness to comply with the study requirements and clinic policies.
8. No evidence of viral hepatitis co-infection as assessed by Hepatitis C antibody, HCV RNA, and hepatitis B surface antigen; determinations at pre-entry visit within 28 days prior to enrollment.
9. No history of or evidence of autoimmune hepatitis or other autoimmune disorders at screening, or Antinuclear antibody (ANA > 3 times upper limit of normal.

10. Laboratory values at pre-entry visit within 14 days prior to enrollment:

    • Alkaline phosphatase < 2.0 times upper limit of normal
    • Alanine transaminase (ALT) < 2.0 times upper limit of normal
    • Total bilirubin < 2.5 mg/dL (< 40 mg/dL if on Atazanavir)
    • Creatinine clearance greater than or equal to 60 mL/min as estimated by the Cockcroft-Gault equation
    • Neutrophil count greater than or equal 1500 cells/mm(3)
    • Platelets greater than or equal to 150,000/ mm(3)
    • Hemoglobin greater than or equal to 12.0 mg/dL for men and > 11.0 g/dL for women
    • Fasting glucose < 126 mg/dL
11. No history or evidence of significant clinical depression at screening that in the opinion of the investigator would affect the ability of the patient to participate in the study, or which would constitute a threat for his/her health in case of relapse upon INF treatment. The Beck Depression Inventory score must be less than or equal to 13 at pre-entry visit.
12. No history of INF/PEG-INF therapy.
13. If capable of pregnancy: use of effective contraception during study: effective contraception methods include abstinence, surgical sterilization of either partner, barrier methods such as diaphragm, condom, cap or sponge, or use of hormonal contraception with an anti-HIV regimen that will not alter metabolism of hormonal contraception.
14. Participants must have primary medical care outside this protocol: participants will have to provide Primary Care Doctor's contact information.

EXCLUSION CRITERIA:

A volunteer will be ineligible to participate in this study if any of the following criteria are met:

1. History of neoplastic disease requiring cytotoxic therapy including hydroxyurea.
2. Use of long-term systemic corticosteroids, immunosuppressive agents, or cytotoxic agents within 60 days prior to enrollment.
3. Any vaccination within 30 days prior to enrollment. Individuals interested in participating who require vaccination will delay screening until 30 day period is completed.
4. Concurrent therapy with investigational cytokines including IL-2 or IL-12 during the course of the study. Prior administration of cytokines is not an exclusion criterion; at least 4 months from most recent cycle of IL-2 or IL-12 is required.
5. History of taking a salvage regimen; i.e., individual has documented drug resistance to antiretrovirals based on genotypic testing; changing antiviral therapy because of adverse effects or intolerance is permitted.
6. Any febrile illness (> 38 degrees C) in the 3 weeks prior to enrollment or any acute therapy for a serious infection completed within 30 days prior to enrollment.
7. Current pregnancy or lactation, history of pregnancy in the last 4 months.
8. Preexisting autoimmune disorders including inflammatory bowel diseases, psoriasis, idiopathic thrombocytopenic purpura, lupus erythematous, autoimmune hemolytic anemia, scleroderma, severe psoriasis, rheumatoid arthritis, and optic neuritis.
9. History of severe retinopathy or evidence of severe retinopathy judged by pre-entry ophthalmologic examination.
10. Known allergy/sensitivity to study drug or its formulation.
11. History of seizure disorders or current anticonvulsant use.
12. Any history of medical conditions associated with chronic liver disease (genetic hemochromatosis, alcoholic liver disease, toxin exposures, and autoimmune hepatitis) or documented cirrhosis due to any cause.
13. History of pulmonary disease associated with functional limitation.
14. Documented history of thyroid disease.
15. Active drug or alcohol use or dependence, which in the opinion of the investigator, would interfere with complying with the study requirements.
16. Known hypersensitivity to Escherichia coli-derived products such as filgrastim.
17. Any systemic illness that will make it unlikely that the subject will be able to return for the required study visits.
18. History of, or any condition that in the opinion of the investigator would interfere with the conduct of the study, or it would not be in the best interest of the subject to enroll in this study.